Expand NNVC Menu
NNVC MENU

NNVC Latest Press Releases

-- December 1, 2025 --

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles ACCESS Newswire 8:30 AM

-- November 17, 2025 --

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position ACCESS Newswire 8:30 AM

-- November 14, 2025 --

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2 ACCESS Newswire 8:30 AM

-- November 12, 2025 --

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close ACCESS Newswire 5:01 PM

-- November 11, 2025 --

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close ACCESS Newswire 8:30 AM

-- November 10, 2025 --

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo ACCESS Newswire 8:30 AM

-- November 5, 2025 --

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT ACCESS Newswire 8:30 AM

-- November 3, 2025 --

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd ACCESS Newswire 8:30 AM

-- October 29, 2025 --

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive ACCESS Newswire 8:45 AM

-- October 27, 2025 --

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 ACCESS Newswire 8:45 AM

-- October 22, 2025 --

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides ACCESS Newswire 8:45 AM

-- October 20, 2025 --

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus ACCESS Newswire 8:45 AM

-- October 15, 2025 --

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses ACCESS Newswire 8:45 AM

-- September 30, 2025 --

NanoViricides, Inc. Has Filed its Annual Report ACCESS Newswire 8:45 AM

-- September 11, 2025 --

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025 ACCESS Newswire 8:30 AM

-- September 9, 2025 --

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025 ACCESS Newswire 8:43 AM
Market Data Delayed 15 Minutes